Nasogastric Decompression Following Pancreaticoduodenectomy (whipple)
Status
Conditions
Treatments
Details and patient eligibility
About
Pancreaticoduodenectomy (PD) remains the gold-standard operation for peri-ampullary neoplasms. Traditionally, gastric decompression via nasogastric intubation has been employed postoperatively to prevent nausea, vomiting, aspiration pneumonia, anastomotic leakage and delayed gastric emptying. Recently, the implementation of ERAS protocol recommended against routine use of nasogastric tube following PD. however, limited data exists surrounding the identification of those patients needing NGT decompression in the immediate postoperative period. Therefore, we initiated a large prospective randomized controlled trial to evaluate the clinical outcomes of patients who retained the NGT post-PD versus those who had it removed at the end of the procedure. This study aims to assess the effectiveness of nasogastric decompression in PD recovery, with the primary endo point being the need for and impact of NGT in the postoperative recovery. The secondary endpoint will examined the re-insertion rate of NGT and identify factors that necessitate its use in the immediate postoperative period.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- All patients 18 years of age or older
- Patients undergoing successful pancreaticoduodenectomy for benign or malignant neoplasm.
Exclusion criteria
- Patients who does not complete the procedure due to locally advanced or metastatic disease discovered during the procedure.
- Patient who requires prolong postoperative intubation in the postoperative period.
Trial design
Primary purpose
Allocation
Interventional model
Masking
230 participants in 2 patient groups
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal